Skip to main content
. 2012 Apr 24;2(2):e000773. doi: 10.1136/bmjopen-2011-000773

Figure 2.

Figure 2

3D-SSP analyses of baseline fluorodeoxyglucose–positron emission tomography in Studies on Diagnosis of Early Alzheimer's Disease—Japan. These are the results of group comparisons between Alzheimer's disease (AD) converters and non-converters. AD converters show a greater reduction in glucose metabolism for AD-associated and frontal regions. This hypometabolism was more evident in the converters within 1 year after inclusion compared with the converters from 1 year to 2 years after inclusion. (A) AD converters within 1 year after inclusion and non-converters. (B) AD converters from 1 year to 2 years after inclusion and non-converters.